Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis
Suman Gupta,Vanessa Yardley,Preeti Vishwakarma,Rahul Shivahare,Bhawna Sharma,Delphine Launay,Denis Martin,Sunil K. Puri +7 more
TLDR
It is revealed that, along with leishmanicidal activity, DNDI-VL-2098 was also capable of inducing host-protective immune cells to suppress Leishmania parasites in hamsters.Abstract:
OBJECTIVES: The objective of this study was to identify a nitroimidazo-oxazole lead molecule for the treatment of visceral leishmaniasis (VL). METHODS: A library of 72 nitroimidazo-oxazoles was evaluated in vitro for their antileishmanial activity against luciferase-transfected DD8 amastigotes of Leishmania donovani. On the basis of their in vitro potency and pharmacokinetic properties, the promising compounds were tested in acute BALB/c mouse and chronic hamster models of VL via oral administration and efficacy was evaluated by microscopic counting of amastigotes after Giemsa staining. The best antileishmanial candidates (racemate DNDI-VL-2001) and its R enantiomer (DNDI-VL-2098) were evaluated in vitro against a range of Leishmania strains. These candidates were further studied in a hamster model using various dose regimens. Cytokine and inducible nitric oxide synthase estimations by real-time PCR and nitric oxide generation by Griess assay were also carried out for DNDI-VL-2098. RESULTS: In vitro screening of nitroimidazo-oxazole compounds identified the racemate DNDI-VL-2001 (6-nitroimidazo-oxazole derivative) and its enantiomers as candidates for further evaluation in in vivo models of VL. DNDI-VL-2098 (IC50 of 0.03 μM for the DD8 strain) showed excellent in vivo activity in both mouse and hamster models, with an ED90 value of 3.7 and <25 mg/kg, respectively, and was also found to be very effective against high-grade infection in the hamster model. Our studies revealed that, along with leishmanicidal activity, DNDI-VL-2098 was also capable of inducing host-protective immune cells to suppress Leishmania parasites in hamsters. CONCLUSIONS: These studies led to the identification of compound DNDI-VL-2098 as a preclinical candidate for further drug development as an oral treatment for VL.read more
Citations
More filters
Journal ArticleDOI
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need
Mark C. Field,David Horn,Alan H. Fairlamb,Michael A. J. Ferguson,David W. Gray,Kevin D. Read,Manu De Rycker,Leah S. Torrie,Paul G. Wyatt,Susan Wyllie,Ian H. Gilbert +10 more
TL;DR: The combination of new drugs, new technologies and public health initiatives is essential for the management, and hopefully eventual elimination, of trypanosomatid diseases from the human population.
Journal ArticleDOI
Nitro-Group-Containing Drugs
TL;DR: The current Perspective covers various aspects of agents that contain nitro groups, their bioreductive activation mechanisms, their toxicities, and approaches to combat their toxicity issues.
Journal ArticleDOI
Chemotherapy of leishmaniasis: present challenges
TL;DR: It is clear that efforts for discovering new drugs applicable to leishmaniasis chemotherapy are essential, and the main aspects on the various steps of drug discovery in the field are discussed.
Journal ArticleDOI
Recent updates and perspectives on leishmaniasis
TL;DR: The diagnostic, chemotherapeutic, and immunizing strategies to control leishmaniasis are highlighted, though no human vaccine is commercially available currently owing to the complexity of the cellular immune response to this parasite.
Journal ArticleDOI
Leishmaniasis drug discovery: recent progress and challenges in assay development.
TL;DR: The in vitro assays currently available have shown poor translational outcomes, with high compound attrition rates, so it is imperative that more physiologically relevant assays are developed to identify anti-leishmanial compounds.
References
More filters
Journal ArticleDOI
Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
TL;DR: A tetrazolium salt has been used to develop a quantitative colorimetric assay for mammalian cell survival and proliferation and is used to measure proliferative lymphokines, mitogen stimulations and complement-mediated lysis.
Journal ArticleDOI
Drug targets and mechanisms of resistance in the anaerobic protozoa
TL;DR: The review examines the value of investigating both clinical and laboratory-induced syngeneic drug-resistant isolates and dissection of the complementary data obtained, as well as thevalue of studies of the epidemiology of resistance.
Journal ArticleDOI
Subversion Mechanisms by Which Leishmania Parasites Can Escape the Host Immune Response: a Signaling Point of View
TL;DR: Some of the signaling pathways and intermediates that are repressed in infected cells are described, including JAK/STAT, Ca2+-dependent protein kinase C (PKC) isoforms, and mitogen-activated protein kinases (especially ERK1/2), and proteasome-mediated transcription factor degradation.
Journal ArticleDOI
A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites
Werner Huber,Jacob C. Koella +1 more
Journal ArticleDOI
Leishmaniasis chemotherapy—challenges and opportunities
TL;DR: There remain challenges to ensure that treatments effective in India are also effective in other regions of the world and to identify treatment for post kala-azar dermal leishmaniasis as well as the opportunity to develop a safe oral short-course treatment.
Related Papers (5)
Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects
Stephen Patterson,Susan Wyllie +1 more
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness
Shilpi Khare,Advait Nagle,Agnes Biggart,Yin H. Lai,Fang Liang,Lauren C. Davis,S. Whitney Barnes,Casey J. N. Mathison,Elmarie Myburgh,Elmarie Myburgh,Mu-Yun Gao,J. Robert Gillespie,Xianzhong Liu,Jocelyn Tan,Monique Stinson,Ianne C. Rivera,Jaime Ballard,Vince Yeh,Todd Groessl,Glenn C. Federe,Hazel X. Y. Koh,John D. Venable,Badry Bursulaya,Michael Shapiro,Pranab Mishra,Glen Spraggon,Ansgar Brock,Jeremy C. Mottram,Jeremy C. Mottram,Frederick S. Buckner,Srinivasa P. S. Rao,Ben G. Wen,John R. Walker,Tove Tuntland,Valentina Molteni,Richard Glynne,Frantisek Supek +36 more